<DOC>
	<DOCNO>NCT00359112</DOCNO>
	<brief_summary>This study compare effect Avandamet ( rosiglitazone maleate/metformin ) treatment metformin plus sulphonylurea treatment overweight people type 2 diabetes .</brief_summary>
	<brief_title>AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Body mass index &gt; = 25 kg/m2 . HbA1c &gt; =7 % &lt; =10 % screening . FPG &gt; = 7.0mmol/L ( 126mg/dL ) visit 2 . Receiving least 0.85g metformin constant dose ( ) least 8 week prior visit 1a . Female subject must postmenopausal use effective contraceptive measure . Exclusion criterion : Use oral antidiabetic drug metformin within 12 week prior screen . Subjects clinically significant ongoing oedema require pharmacological treatment history oedema require pharmacological treatment . Subjects history severe hypoglycaemia . Renal disease renal dysfunction . Presence clinically significant hepatic disease . Presence unstable severe angina know NYHA grade IIV congestive heart failure . Subjects previous myocardial infarction , percutaneous transluminal coronary angioplasty , coronary artery bypass graft cerebrovascular accident within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>overweight</keyword>
	<keyword>AVANDAMET</keyword>
	<keyword>metformin</keyword>
	<keyword>sulphonylurea</keyword>
</DOC>